Followers | 42 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
Thursday, December 09, 2021 7:20:45 AM
From time to time the Company is subject to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.
On March 12, 2021, the Company and Mr. Mack (the “Defendants”) were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”), and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware. In the Complaint, the Plaintiffs alleged (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021 Plaintiffs filed an Amended Complaint (the “First Amended Complaint”) asserting the same three causes of action. Simultaneously with filing the original Complaint, Plaintiffs filed a motion to expedite, seeking a hearing on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting the alleged tortious interference. On March 22, 2021, Vice Chancellor Paul A. Fioravanti Jr. issued a scheduling order, setting forth terms which had been agreed to by the parties, under which oral argument on Plaintiffs’ proposed motion for preliminary injunction was scheduled for July 15, 2021. On May 18, 2021, the Vice Chancellor issued a revised scheduling order, also setting forth terms which had been agreed to by the parties, under which Plaintiffs agreed not to move for a preliminary injunction and a trial in the action was set for February 9-11, 2022. On September 28, 2021, Plaintiffs filed a Second Amended Verified Complaint asserting the same three causes of action as the prior complaints, as well as additional claims in which Plaintiffs allege (i) Mr. Mack breached an Employment, Proprietary Information and Inventions Agreement, dated as of October 25, 2016, between himself and Sorrento (the “Employment Agreement”), (ii) the Company tortiously interfered with the Employment Agreement, (iii) Mr. Mack breached his fiduciary duties to Scilex, and (iv) the Company aided and abetted Mr. Mack’s alleged breach of fiduciary duties to Scilex. On October 18, 2021, Defendants filed an Answer to the Second Amended Complaint, and subsequently withdrew a previously filed motion to dismiss the first Amended Complaint. We intend to vigorously defend the action. However, we are unable to predict the ultimate outcome of the lawsuit at this time.
“
- From the quarterly filing
my posts are always theory and not financial advice
Recent VRPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 08:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 08:11:50 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/13/2024 01:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:35:20 AM
- Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments • Business Wire • 08/13/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:26:43 PM
- Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 • Business Wire • 08/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:26:23 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 08:30:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:31:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:45:16 AM
- Virpax Regains Compliance with Nasdaq Minimum Bid Price • Business Wire • 07/24/2024 11:30:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 10:40:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 12:00:17 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 07/12/2024 08:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 08:10:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 08:09:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 04:48:25 PM
- Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™ • Business Wire • 07/10/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:02:40 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:00:39 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/08/2024 08:32:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:30:21 AM
- Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding • Business Wire • 07/08/2024 11:30:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM